News & Media

Newsroom

SK Biopharmaceuticals Wins Export Award for Cenobamate

12.6.2022

Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals’ Seizure Detection Wearable Device at AES 2022

12.5.2022

SK life science Presents Latest Data on XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AES 2022 Annual Meeting

12.2.2022

SK Biopharmaceuticals Names Donghoon Lee, Head of Bio Investment Center of SK Inc., as New CEO

12.1.2022

SK life science To Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Epilepsy Society 2022 Annual Meeting

11.28.2022

Welcome to the news and information center for SK Life Science, Inc.

To learn more about SK Life Science, please download our corporate fact sheet

For more information about epilepsy, please download this infographic

For more information about Lennox-Gastaut syndrome, please download this fact sheet

X Community Guidelines

LinkedIn Community Guidelines

SK Life Science at a Glance

Headquarters Location: Paramus, NJ

R&D Begins: 1993

Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, CO., LTD, and both are a part of SK Group

Number of Employees: 200+ Employees

Disease Category Focus: CNS Disorders and Oncology

Pipeline: 8 compounds under clinical development

Top